{"id": "article-25045_0", "title": "Metachromatic Leukodystrophy -- Continuing Education Activity", "content": "Metachromatic leukodystrophy is a rare lysosomal storage disease caused due to deficient activity of arylsulfatase A. It follows an autosomal recessive pattern of inheritance. It is a serious condition and causes death within 5-6 years in early-onset form. Prompt diagnosis and treatment hel in achieving a better quality of life. This activity describes the etiology, evaluation, and management of metachromatic leukodystrophy and highlights the role of the interprofessional team in evaluating and treating the patients with this condition.", "contents": "Metachromatic Leukodystrophy -- Continuing Education Activity. Metachromatic leukodystrophy is a rare lysosomal storage disease caused due to deficient activity of arylsulfatase A. It follows an autosomal recessive pattern of inheritance. It is a serious condition and causes death within 5-6 years in early-onset form. Prompt diagnosis and treatment hel in achieving a better quality of life. This activity describes the etiology, evaluation, and management of metachromatic leukodystrophy and highlights the role of the interprofessional team in evaluating and treating the patients with this condition."}
{"id": "article-25045_1", "title": "Metachromatic Leukodystrophy -- Continuing Education Activity", "content": "Objectives: Describe the etiology of metachromatic leukodystrophy. Describe the evaluation of metachromatic leukodystrophy. Outline the management options available for metachromatic leukodystrophy. Access free multiple choice questions on this topic.", "contents": "Metachromatic Leukodystrophy -- Continuing Education Activity. Objectives: Describe the etiology of metachromatic leukodystrophy. Describe the evaluation of metachromatic leukodystrophy. Outline the management options available for metachromatic leukodystrophy. Access free multiple choice questions on this topic."}
{"id": "article-25045_2", "title": "Metachromatic Leukodystrophy -- Introduction", "content": "Lysosomal storage diseases (LSDs) are a group of hereditary disorders that disrupt lysosomal function, specifically, enzymes involved in cell metabolism, signaling, substrate processing, innate immunity, apoptosis, and other complex cell recycling processes. This process is extremely complex.\u00a0The accumulation of undigested or partially processed molecules become toxic for the host cell. The onset tends to predominate in early infancy or childhood, with some disease onset in adulthood. LSDs tend to have a progressive neurodegenerative course and can cause multi-organ failure and, ultimately, death. [1]", "contents": "Metachromatic Leukodystrophy -- Introduction. Lysosomal storage diseases (LSDs) are a group of hereditary disorders that disrupt lysosomal function, specifically, enzymes involved in cell metabolism, signaling, substrate processing, innate immunity, apoptosis, and other complex cell recycling processes. This process is extremely complex.\u00a0The accumulation of undigested or partially processed molecules become toxic for the host cell. The onset tends to predominate in early infancy or childhood, with some disease onset in adulthood. LSDs tend to have a progressive neurodegenerative course and can cause multi-organ failure and, ultimately, death. [1]"}
{"id": "article-25045_3", "title": "Metachromatic Leukodystrophy -- Introduction", "content": "Leukodystrophies are inherited disorders that predominantly affect the central nervous system (CNS) white matter tracts, and it's cellular components. These may include\u00a0glial cells, myelin sheath, and axons. Genetic leukodystrophies tend to\u00a0combine features of leukodystrophies with development issues caused by inborn errors of metabolism, disorders of DNA transcription, translation, production of critical CNS proteins including myelin, and neuronal cytoskeletal dysfunction.", "contents": "Metachromatic Leukodystrophy -- Introduction. Leukodystrophies are inherited disorders that predominantly affect the central nervous system (CNS) white matter tracts, and it's cellular components. These may include\u00a0glial cells, myelin sheath, and axons. Genetic leukodystrophies tend to\u00a0combine features of leukodystrophies with development issues caused by inborn errors of metabolism, disorders of DNA transcription, translation, production of critical CNS proteins including myelin, and neuronal cytoskeletal dysfunction."}
{"id": "article-25045_4", "title": "Metachromatic Leukodystrophy -- Introduction", "content": "Metachromatic leukodystrophy is a demyelinating, autosomal recessive genetic leukodystrophy and LSD, caused by an inborn error of metabolism in the arylsulfatase A lysosomal enzyme. This leads to the accumulation of sulfatides, which result in the dysfunction and destruction of the CNS/PNS myelin sheaths. It also accumulates in other organs, including the\u00a0kidneys, testes, and gallbladder.\u00a0It can be classified based on the age of onset and clinical features of the disease.\u00a0All forms of the disease involve a progressive deterioration of neurodevelopment and neurocognitive function. [2]", "contents": "Metachromatic Leukodystrophy -- Introduction. Metachromatic leukodystrophy is a demyelinating, autosomal recessive genetic leukodystrophy and LSD, caused by an inborn error of metabolism in the arylsulfatase A lysosomal enzyme. This leads to the accumulation of sulfatides, which result in the dysfunction and destruction of the CNS/PNS myelin sheaths. It also accumulates in other organs, including the\u00a0kidneys, testes, and gallbladder.\u00a0It can be classified based on the age of onset and clinical features of the disease.\u00a0All forms of the disease involve a progressive deterioration of neurodevelopment and neurocognitive function. [2]"}
{"id": "article-25045_5", "title": "Metachromatic Leukodystrophy -- Etiology", "content": "Metachromatic leukodystrophy is caused by deficient activity of arylsulfatase A. In almost all cases, mutations are in the arylsulfatase A gene (ARSA gene), on chromosome 22q13.3-qter. Two alleles, A and I have contributed to approximately 50 percent of cases and are responsible for different clinical expression of the disease. [3] In some cases, it is due to the deficiency of sphingolipid activator protein SAP-B (saposin B), which is responsible for the degradation of sulfatides by ARSA. This form is caused by mutations in the prosaposin gene (PSAP gene). [4] [5]", "contents": "Metachromatic Leukodystrophy -- Etiology. Metachromatic leukodystrophy is caused by deficient activity of arylsulfatase A. In almost all cases, mutations are in the arylsulfatase A gene (ARSA gene), on chromosome 22q13.3-qter. Two alleles, A and I have contributed to approximately 50 percent of cases and are responsible for different clinical expression of the disease. [3] In some cases, it is due to the deficiency of sphingolipid activator protein SAP-B (saposin B), which is responsible for the degradation of sulfatides by ARSA. This form is caused by mutations in the prosaposin gene (PSAP gene). [4] [5]"}
{"id": "article-25045_6", "title": "Metachromatic Leukodystrophy -- Epidemiology", "content": "The prevalence of metachromatic leukodystrophy ranges from 1/40,000 to 1/100,000 in the northern European and North American populations. [6] Incidence is estimated to be 1/40,000 births in the United States of America. There is no sexual and racial predilection. The disease is categorized based on the age of onset. Late Infantile form : 6 months\u00a0to 4 years of age. Juvenile form : Early Juvenile: 4\u00a0to 6 years of age. Late Juvenile: 6\u00a0to 16 years of age. Adult form : Beyond 16 years of age.", "contents": "Metachromatic Leukodystrophy -- Epidemiology. The prevalence of metachromatic leukodystrophy ranges from 1/40,000 to 1/100,000 in the northern European and North American populations. [6] Incidence is estimated to be 1/40,000 births in the United States of America. There is no sexual and racial predilection. The disease is categorized based on the age of onset. Late Infantile form : 6 months\u00a0to 4 years of age. Juvenile form : Early Juvenile: 4\u00a0to 6 years of age. Late Juvenile: 6\u00a0to 16 years of age. Adult form : Beyond 16 years of age."}
{"id": "article-25045_7", "title": "Metachromatic Leukodystrophy -- Pathophysiology", "content": "Metachromatic leukodystrophy is a lysosomal storage disease characterized by the inability to\u00a0degrade sulfated glycolipids, mainly\u00a0the galactosyl-3-sulfate ceramides. It is caused by deficient activity of lysosomal enzyme arylsulfatase A, most commonly due to mutations in the arylsulfatase A (ARSA gene). During the process, the sulfated glycolipids are degraded into galactocerebroside by the enzyme Arylsulfatase A.", "contents": "Metachromatic Leukodystrophy -- Pathophysiology. Metachromatic leukodystrophy is a lysosomal storage disease characterized by the inability to\u00a0degrade sulfated glycolipids, mainly\u00a0the galactosyl-3-sulfate ceramides. It is caused by deficient activity of lysosomal enzyme arylsulfatase A, most commonly due to mutations in the arylsulfatase A (ARSA gene). During the process, the sulfated glycolipids are degraded into galactocerebroside by the enzyme Arylsulfatase A."}
{"id": "article-25045_8", "title": "Metachromatic Leukodystrophy -- Histopathology", "content": "Metachromatic granules may be seen in the tissue specimen. In the nervous system, the loss of myelinated oligodendrocytes is seen.", "contents": "Metachromatic Leukodystrophy -- Histopathology. Metachromatic granules may be seen in the tissue specimen. In the nervous system, the loss of myelinated oligodendrocytes is seen."}
{"id": "article-25045_9", "title": "Metachromatic Leukodystrophy -- History and Physical", "content": "Leukodystrophies are generally suspected in pediatric patients with difficulties in meeting\u00a0appropriate development milestones when previously was able to do so.\u00a0Peripheral neuropathy can present prior to dysarthria and other CNS manifestations. [7] [8] A decline in gross and fine motor skills at any age should be evaluated for metachromatic leukodystrophy.\u00a0Clinical manifestations of the diseases can be categorized by the age at which the disease onset. [9]", "contents": "Metachromatic Leukodystrophy -- History and Physical. Leukodystrophies are generally suspected in pediatric patients with difficulties in meeting\u00a0appropriate development milestones when previously was able to do so.\u00a0Peripheral neuropathy can present prior to dysarthria and other CNS manifestations. [7] [8] A decline in gross and fine motor skills at any age should be evaluated for metachromatic leukodystrophy.\u00a0Clinical manifestations of the diseases can be categorized by the age at which the disease onset. [9]"}
{"id": "article-25045_10", "title": "Metachromatic Leukodystrophy -- History and Physical", "content": "Late infantile onset : Onset < 30 months. Typically early milestones are met, followed by a progressive regression of motor skills, ataxia, dysarthria, hypotonia, spasticity, hypotonia, hyporeflexia, extensor plantar posturing, and optic atrophy. [10] Accounts for approximately 50% of cases. Neuropsychiatric testing can uncover these deficits.", "contents": "Metachromatic Leukodystrophy -- History and Physical. Late infantile onset : Onset < 30 months. Typically early milestones are met, followed by a progressive regression of motor skills, ataxia, dysarthria, hypotonia, spasticity, hypotonia, hyporeflexia, extensor plantar posturing, and optic atrophy. [10] Accounts for approximately 50% of cases. Neuropsychiatric testing can uncover these deficits."}
{"id": "article-25045_11", "title": "Metachromatic Leukodystrophy -- History and Physical", "content": "Juvenile onset : Onset between 30 months and puberty, with a heterogeneous presentation. Early milestones are met, followed by psychomotor regression, intellectual decline (e.g., dropped school performance), behavioral difficulties, personality changes, ataxia, upper motor neuron signs, and peripheral neuropathy. In late juvenile-onset, the patient presents similarly, with +/- seizures.\u00a0Neurocognitive tests demonstrate dementia, memory loss, disinhibition, impulsiveness, decreased motor function, and optic atrophy. [11]", "contents": "Metachromatic Leukodystrophy -- History and Physical. Juvenile onset : Onset between 30 months and puberty, with a heterogeneous presentation. Early milestones are met, followed by psychomotor regression, intellectual decline (e.g., dropped school performance), behavioral difficulties, personality changes, ataxia, upper motor neuron signs, and peripheral neuropathy. In late juvenile-onset, the patient presents similarly, with +/- seizures.\u00a0Neurocognitive tests demonstrate dementia, memory loss, disinhibition, impulsiveness, decreased motor function, and optic atrophy. [11]"}
{"id": "article-25045_12", "title": "Metachromatic Leukodystrophy -- History and Physical", "content": "Adult onset : Adult-onset (can present as early as adolescence) shows neurocognitive and neuropsychiatric\u00a0difficulties. Patients may have dysesthesias (peripheral neuropathy), psychosis, schizophrenia, or seizures. It is frequently misdiagnosed with bipolar disorder and dementia. Tends to be exclusively neuropsychiatric with minimal or no motor findings. Neurocognitive tests in this group of patients present similar to the juvenile onset group.", "contents": "Metachromatic Leukodystrophy -- History and Physical. Adult onset : Adult-onset (can present as early as adolescence) shows neurocognitive and neuropsychiatric\u00a0difficulties. Patients may have dysesthesias (peripheral neuropathy), psychosis, schizophrenia, or seizures. It is frequently misdiagnosed with bipolar disorder and dementia. Tends to be exclusively neuropsychiatric with minimal or no motor findings. Neurocognitive tests in this group of patients present similar to the juvenile onset group."}
{"id": "article-25045_13", "title": "Metachromatic Leukodystrophy -- Evaluation", "content": "Laboratory Studies :", "contents": "Metachromatic Leukodystrophy -- Evaluation. Laboratory Studies :"}
{"id": "article-25045_14", "title": "Metachromatic Leukodystrophy -- Evaluation", "content": "Arylsulfatase A enzyme activity in leukocytes or cultured skin fibroblasts may be decreased. [12] Values generally range from undetectable to less than 10 percent of the normal values. However,\u00a0Metachromatic Leukodystrophy must be distinguished from arylsulfatase A pseudo deficiency (present in approximately one percent of the general population).\u00a0Patients\u00a0with arylsulfatase A pseudo deficiency has arylsulfatase A levels ranging from 5% to 20% of normal values without clinical or radiographic disease. The\u00a0followings tests can be used to differentiate them: Urine sulfatide levels Radiolabeled sulfatide fibroblast loading DNA mutation analysis or next-generation sequencing-\u00a0biallelic ARSA pathogenic variants", "contents": "Metachromatic Leukodystrophy -- Evaluation. Arylsulfatase A enzyme activity in leukocytes or cultured skin fibroblasts may be decreased. [12] Values generally range from undetectable to less than 10 percent of the normal values. However,\u00a0Metachromatic Leukodystrophy must be distinguished from arylsulfatase A pseudo deficiency (present in approximately one percent of the general population).\u00a0Patients\u00a0with arylsulfatase A pseudo deficiency has arylsulfatase A levels ranging from 5% to 20% of normal values without clinical or radiographic disease. The\u00a0followings tests can be used to differentiate them: Urine sulfatide levels Radiolabeled sulfatide fibroblast loading DNA mutation analysis or next-generation sequencing-\u00a0biallelic ARSA pathogenic variants"}
{"id": "article-25045_15", "title": "Metachromatic Leukodystrophy -- Evaluation -- Imaging Studies", "content": "Brain MRI shows T2-weighted FLAIR symmetric and confluent hyperintensities diffusely on the frontal and parietal periventricular white matter, which are characteristic of the diseases but nonspecific. T1-weighted images tend to be hypointense, given it is a demyelinating disorder. A\u00a0normal MRI does not exclude metachromatic leukodystrophy. [13] Ultrasound or CT abdomen may reveal hyperplastic gallbladder polyps, which can predispose for gallbladder carcinoma. [14]", "contents": "Metachromatic Leukodystrophy -- Evaluation -- Imaging Studies. Brain MRI shows T2-weighted FLAIR symmetric and confluent hyperintensities diffusely on the frontal and parietal periventricular white matter, which are characteristic of the diseases but nonspecific. T1-weighted images tend to be hypointense, given it is a demyelinating disorder. A\u00a0normal MRI does not exclude metachromatic leukodystrophy. [13] Ultrasound or CT abdomen may reveal hyperplastic gallbladder polyps, which can predispose for gallbladder carcinoma. [14]"}
{"id": "article-25045_16", "title": "Metachromatic Leukodystrophy -- Evaluation -- Additional Tests", "content": "The following tests can be conducted with could further help in diagnosing the case. Nerve conduction and ENG studies EMG- can show a demyelinating polyneuropathy pattern affecting both compound muscle (CMAPs) and sensory action potentials (SNAPs) Neurocognitive, neuropsychological testing, or both", "contents": "Metachromatic Leukodystrophy -- Evaluation -- Additional Tests. The following tests can be conducted with could further help in diagnosing the case. Nerve conduction and ENG studies EMG- can show a demyelinating polyneuropathy pattern affecting both compound muscle (CMAPs) and sensory action potentials (SNAPs) Neurocognitive, neuropsychological testing, or both"}
{"id": "article-25045_17", "title": "Metachromatic Leukodystrophy -- Evaluation -- Procedures", "content": "Lumbar Puncture:  Elevated cerebrospinal fluid protein concentrations may be helpful to arrive at the diagnosis. Peripheral nerve biopsy: usually not performed, but may show\u00a0metachromatic lipid deposits", "contents": "Metachromatic Leukodystrophy -- Evaluation -- Procedures. Lumbar Puncture:  Elevated cerebrospinal fluid protein concentrations may be helpful to arrive at the diagnosis. Peripheral nerve biopsy: usually not performed, but may show\u00a0metachromatic lipid deposits"}
{"id": "article-25045_18", "title": "Metachromatic Leukodystrophy -- Evaluation -- Newborn Screening", "content": "It is still under development. It uses mass spectrometry. However, it can not be distinguished from pseudo deficiency. [15]", "contents": "Metachromatic Leukodystrophy -- Evaluation -- Newborn Screening. It is still under development. It uses mass spectrometry. However, it can not be distinguished from pseudo deficiency. [15]"}
{"id": "article-25045_19", "title": "Metachromatic Leukodystrophy -- Treatment / Management", "content": "No curative treatment options are currently available for this disease\u2014the focus in the enhancement of the quality of life by focusing on symptom management.\u00a0Symptomatic supportive care is needed to address to neurocognitive and neuropsychiatric disturbances, seizures, dystonias, spasticity, feeding problems, and constipation.", "contents": "Metachromatic Leukodystrophy -- Treatment / Management. No curative treatment options are currently available for this disease\u2014the focus in the enhancement of the quality of life by focusing on symptom management.\u00a0Symptomatic supportive care is needed to address to neurocognitive and neuropsychiatric disturbances, seizures, dystonias, spasticity, feeding problems, and constipation."}
{"id": "article-25045_20", "title": "Metachromatic Leukodystrophy -- Treatment / Management -- Symptomatic Treatment", "content": "Seizures - broad spectrum anti-epileptics such as levetiracetam, zonisamide, lacosamide, and valproic acid Spasticity - baclofen, cyclobenzaprine, botox toxin A Dystonia - botox toxin A Dysautonomia (drooling, orthostasis) - anticholinergic therapy, oral midodrine or fludrocortisone, Pain - NSAIDs, gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors (SNRIs), etc Nutrition and GI issues - percutaneous feeding tubes, famotidine or pantoprazole, bowel regimen (docusate, senna) Insomnia/mood issues - SNRI such as mirtazapine, tricyclic anti-depressants (TCAs), serotonin reuptake inhibitors (SSRI), etc Arthralgias/myalgias, mobility, functional impairments in activities of daily living - physical, occupational, cognitive, and gait therapy [16]", "contents": "Metachromatic Leukodystrophy -- Treatment / Management -- Symptomatic Treatment. Seizures - broad spectrum anti-epileptics such as levetiracetam, zonisamide, lacosamide, and valproic acid Spasticity - baclofen, cyclobenzaprine, botox toxin A Dystonia - botox toxin A Dysautonomia (drooling, orthostasis) - anticholinergic therapy, oral midodrine or fludrocortisone, Pain - NSAIDs, gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors (SNRIs), etc Nutrition and GI issues - percutaneous feeding tubes, famotidine or pantoprazole, bowel regimen (docusate, senna) Insomnia/mood issues - SNRI such as mirtazapine, tricyclic anti-depressants (TCAs), serotonin reuptake inhibitors (SSRI), etc Arthralgias/myalgias, mobility, functional impairments in activities of daily living - physical, occupational, cognitive, and gait therapy [16]"}
{"id": "article-25045_21", "title": "Metachromatic Leukodystrophy -- Treatment / Management -- Genetic Counseling", "content": "MLD is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing of at-risk family members and prenatal testing for a pregnancy at increased risk are possible if both ARSA pathogenic variants have been identified in an affected family member.", "contents": "Metachromatic Leukodystrophy -- Treatment / Management -- Genetic Counseling. MLD is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing of at-risk family members and prenatal testing for a pregnancy at increased risk are possible if both ARSA pathogenic variants have been identified in an affected family member."}
{"id": "article-25045_22", "title": "Metachromatic Leukodystrophy -- Treatment / Management -- Experimental and emerging therapies:", "content": "A combination of gene therapy and hematopoietic stem cell transplantation (HSCT) - Offers the most promise at this time. The benefits may be more apparent in the asymptomatic or early symptomatic juvenile-onset disease. HSCT is not recommended for individuals with symptomatic, late-infantile form. Studies show that patients with juvenile disease may have a 5-year survival of\u00a0approximately 59%. However, many patients\u00a0decline post-transplant (based on measures such as imaging, gross motor function, cognitive skills, nerve conduction velocities, and other metrics). Therefore, the neurocognitive function may be stabilized by bone marrow transplantation; however, there is still a progressive loss of the motor function. In late juvenile and adult-onset forms, bone marrow transplantation may slow the disease progression. [17] [18] Phase I/II clinical trial gene therapy (using retroviral vector technology) plus\u00a0autologous hematopoietic stem cell transplantation: A study of asymptomatic late-onset infantile disease, juvenile disease, and early-onset juvenile disease that showed delayed onset of\u00a0MRI abnormalities and recovery of some gross motor function and cognition. [19] [20]", "contents": "Metachromatic Leukodystrophy -- Treatment / Management -- Experimental and emerging therapies:. A combination of gene therapy and hematopoietic stem cell transplantation (HSCT) - Offers the most promise at this time. The benefits may be more apparent in the asymptomatic or early symptomatic juvenile-onset disease. HSCT is not recommended for individuals with symptomatic, late-infantile form. Studies show that patients with juvenile disease may have a 5-year survival of\u00a0approximately 59%. However, many patients\u00a0decline post-transplant (based on measures such as imaging, gross motor function, cognitive skills, nerve conduction velocities, and other metrics). Therefore, the neurocognitive function may be stabilized by bone marrow transplantation; however, there is still a progressive loss of the motor function. In late juvenile and adult-onset forms, bone marrow transplantation may slow the disease progression. [17] [18] Phase I/II clinical trial gene therapy (using retroviral vector technology) plus\u00a0autologous hematopoietic stem cell transplantation: A study of asymptomatic late-onset infantile disease, juvenile disease, and early-onset juvenile disease that showed delayed onset of\u00a0MRI abnormalities and recovery of some gross motor function and cognition. [19] [20]"}
{"id": "article-25045_23", "title": "Metachromatic Leukodystrophy -- Treatment / Management", "content": "Gene therapy, enzyme replacement, and small molecule therapy (e.g., substrate reduction and chaperone therapies)", "contents": "Metachromatic Leukodystrophy -- Treatment / Management. Gene therapy, enzyme replacement, and small molecule therapy (e.g., substrate reduction and chaperone therapies)"}
{"id": "article-25045_24", "title": "Metachromatic Leukodystrophy -- Treatment / Management", "content": "Hence, preliminary evidence suggests that gene therapy and hematopoietic stem cell transplantation combined with gene therapy are promising treatment options. [21] However, the cellular pathogenesis of metachromatic leukodystrophy is complex. Several other LSDs have used disease-specific gene and enzyme replacement therapies with some success. Small-molecule therapies are emergent therapy for some LSDs. Although gene therapy and genome microRNA editing\u00a0are at advanced preclinical stages, there is a need for phase III/IV clinical trials.", "contents": "Metachromatic Leukodystrophy -- Treatment / Management. Hence, preliminary evidence suggests that gene therapy and hematopoietic stem cell transplantation combined with gene therapy are promising treatment options. [21] However, the cellular pathogenesis of metachromatic leukodystrophy is complex. Several other LSDs have used disease-specific gene and enzyme replacement therapies with some success. Small-molecule therapies are emergent therapy for some LSDs. Although gene therapy and genome microRNA editing\u00a0are at advanced preclinical stages, there is a need for phase III/IV clinical trials."}
{"id": "article-25045_25", "title": "Metachromatic Leukodystrophy -- Differential Diagnosis", "content": "Metachromatic leukodystrophy must be differentiated from other LSDs with similar presentation and with\u00a0arylsulfatase A pseudodeficiency. Arylsulfatase A pseudodeficiency can be differentiated using\u00a0gene mutation analysis or evaluation of radiolabeled sulfatide fibroblast uptake and accumulation. Other differentials that must be kept in mind while diagnosing metachromatic leukodystrophy are: Krabbe diseases: [22] [23] LSD that is\u00a0autosomal-recessive, caused by deficient activity of the beta-galactosidase. Clinically it presents with irritability, hypertonia, hyperesthesia, and psychomotor arrest.", "contents": "Metachromatic Leukodystrophy -- Differential Diagnosis. Metachromatic leukodystrophy must be differentiated from other LSDs with similar presentation and with\u00a0arylsulfatase A pseudodeficiency. Arylsulfatase A pseudodeficiency can be differentiated using\u00a0gene mutation analysis or evaluation of radiolabeled sulfatide fibroblast uptake and accumulation. Other differentials that must be kept in mind while diagnosing metachromatic leukodystrophy are: Krabbe diseases: [22] [23] LSD that is\u00a0autosomal-recessive, caused by deficient activity of the beta-galactosidase. Clinically it presents with irritability, hypertonia, hyperesthesia, and psychomotor arrest."}
{"id": "article-25045_26", "title": "Metachromatic Leukodystrophy -- Differential Diagnosis", "content": "X-linked adrenoleukodystrophy: [24] [25] Primarily affects boys, it is a leukodystrophy that presents with adrenal insufficiency, neurocognitive (low IQ) and neurobehavioral issues (ADHD-like behavior), dysarthria, dysgraphia, deficits in vision, hearing. They are found to have elevated very-long-chain fatty acids (VLCFA), abnormal white matter disease on MRI, and a pathogenic variant of the ABCD1 gene on molecular genetic testing. Canavan disease: [26] [27] Primarily affecting the Ashkenazi Jewish population, it is an infantile autosomal-recessive leukodystrophy characterized by intellectual disability, irritability, macrocephaly, dysphagia, early hypotonia, late spasticity, ataxia, seizures, and optic atrophy. It is\u00a0progressive and neurodegenerative in nature. Typically they have\u00a0elevated N-acetyl aspartate (NAA) in urine, abnormal diffuse white matter disease on MRI, and pathogenic variants in ASPA on molecular genetic testing.", "contents": "Metachromatic Leukodystrophy -- Differential Diagnosis. X-linked adrenoleukodystrophy: [24] [25] Primarily affects boys, it is a leukodystrophy that presents with adrenal insufficiency, neurocognitive (low IQ) and neurobehavioral issues (ADHD-like behavior), dysarthria, dysgraphia, deficits in vision, hearing. They are found to have elevated very-long-chain fatty acids (VLCFA), abnormal white matter disease on MRI, and a pathogenic variant of the ABCD1 gene on molecular genetic testing. Canavan disease: [26] [27] Primarily affecting the Ashkenazi Jewish population, it is an infantile autosomal-recessive leukodystrophy characterized by intellectual disability, irritability, macrocephaly, dysphagia, early hypotonia, late spasticity, ataxia, seizures, and optic atrophy. It is\u00a0progressive and neurodegenerative in nature. Typically they have\u00a0elevated N-acetyl aspartate (NAA) in urine, abnormal diffuse white matter disease on MRI, and pathogenic variants in ASPA on molecular genetic testing."}
{"id": "article-25045_27", "title": "Metachromatic Leukodystrophy -- Differential Diagnosis", "content": "Peroxisomal biogenesis disorders (e.g. Zellweger disease): [28] [29] Leukodystrophy caused by a mutation in one out of\u00a013 different PEX genes, PEX1 being the most common, leading to dysfunctional peroxisomes. Clinical symptoms may include intellectual delay, craniofacial dysmorphia, retinopathy (e.g. glaucoma, retinitis pigmentosa), visual blindness, sensorineural deafness, hypotonia, hepatomegaly with coagulopathy, diffuse jaundice, dysphagia, chondrodysplasia punctata, and seizures.\u00a0MRI can show neocortical dysplasia, diffuse white matter atrophy, and ventriculomegaly with cysts. Elevated transaminases and hyperbilirubinemia are common.", "contents": "Metachromatic Leukodystrophy -- Differential Diagnosis. Peroxisomal biogenesis disorders (e.g. Zellweger disease): [28] [29] Leukodystrophy caused by a mutation in one out of\u00a013 different PEX genes, PEX1 being the most common, leading to dysfunctional peroxisomes. Clinical symptoms may include intellectual delay, craniofacial dysmorphia, retinopathy (e.g. glaucoma, retinitis pigmentosa), visual blindness, sensorineural deafness, hypotonia, hepatomegaly with coagulopathy, diffuse jaundice, dysphagia, chondrodysplasia punctata, and seizures.\u00a0MRI can show neocortical dysplasia, diffuse white matter atrophy, and ventriculomegaly with cysts. Elevated transaminases and hyperbilirubinemia are common."}
{"id": "article-25045_28", "title": "Metachromatic Leukodystrophy -- Differential Diagnosis", "content": "Polyglucosan body disease: [30] [31] An\u00a0autosomal recessive adult-onset disease characterized by progressive neurogenic bladder, gait difficulties (e.g. spasticity and weakness) from mixed upper and lower motor neuron involvement, sensory loss predominantly in the distal lower extremities, and some cognitive difficulties (often executive dysfunction). MRI of the brain and spinal cord, and sural nerve biopsy shows clusters of\u00a0polyglucosan deposition. The glycogen brancher enzyme (GBE) activity in skin fibroblasts is abnormal, and molecular genetic testing reveals a mutation in GBE1. Fucosidosis: [32] [33]  very rare, caused by FUCA1 mutation, characterized by coarse facies, recurrent opportunistic infections,\u00a0generalized dystonia, spasticity, dysostosis multiplex, diffuse angiokeratoma, and organomegaly", "contents": "Metachromatic Leukodystrophy -- Differential Diagnosis. Polyglucosan body disease: [30] [31] An\u00a0autosomal recessive adult-onset disease characterized by progressive neurogenic bladder, gait difficulties (e.g. spasticity and weakness) from mixed upper and lower motor neuron involvement, sensory loss predominantly in the distal lower extremities, and some cognitive difficulties (often executive dysfunction). MRI of the brain and spinal cord, and sural nerve biopsy shows clusters of\u00a0polyglucosan deposition. The glycogen brancher enzyme (GBE) activity in skin fibroblasts is abnormal, and molecular genetic testing reveals a mutation in GBE1. Fucosidosis: [32] [33]  very rare, caused by FUCA1 mutation, characterized by coarse facies, recurrent opportunistic infections,\u00a0generalized dystonia, spasticity, dysostosis multiplex, diffuse angiokeratoma, and organomegaly"}
{"id": "article-25045_29", "title": "Metachromatic Leukodystrophy -- Differential Diagnosis", "content": "Childhood-onset schizophrenia: [34] Childhood-onset schizophrenia is a severe form of psychotic disorder that occurs at age 12 years or younger. It has some neurologic features and has to be differentiated from metachromatic leukodystrophy. Schizophrenia presents with delusion, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms.", "contents": "Metachromatic Leukodystrophy -- Differential Diagnosis. Childhood-onset schizophrenia: [34] Childhood-onset schizophrenia is a severe form of psychotic disorder that occurs at age 12 years or younger. It has some neurologic features and has to be differentiated from metachromatic leukodystrophy. Schizophrenia presents with delusion, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms."}
{"id": "article-25045_30", "title": "Metachromatic Leukodystrophy -- Prognosis", "content": "Metachromatic leukodystrophy is a progressive disease. This means that the symptoms tend to get worse over time. People who have this disease lose all muscle and mental functions eventually. Lifespan often depends on the age at which a person is first diagnosed. Late infantile form : The prognosis is worse than later-onset forms of the diseases; progression to death typically occurs within five to six years. Juvenile form : Progression is slower in this form of the disease, and the patients may survive until early adulthood. Adult form : The disease course in this form of the disease may be static or of insidious progression.", "contents": "Metachromatic Leukodystrophy -- Prognosis. Metachromatic leukodystrophy is a progressive disease. This means that the symptoms tend to get worse over time. People who have this disease lose all muscle and mental functions eventually. Lifespan often depends on the age at which a person is first diagnosed. Late infantile form : The prognosis is worse than later-onset forms of the diseases; progression to death typically occurs within five to six years. Juvenile form : Progression is slower in this form of the disease, and the patients may survive until early adulthood. Adult form : The disease course in this form of the disease may be static or of insidious progression."}
{"id": "article-25045_31", "title": "Metachromatic Leukodystrophy -- Complications", "content": "Therapies focus on the quality of life, and functional activities of daily living can help in areas of mobility, cognition, communication, and oral intake. Safety measures are to avoid falls at home. The most common complications of the disease include: Neurocognitive decline (dementia) Blindness (e.g., optic atrophy) Malnutrition Aspiration pneumonia Death (5 to 6 years in the late infantile form)", "contents": "Metachromatic Leukodystrophy -- Complications. Therapies focus on the quality of life, and functional activities of daily living can help in areas of mobility, cognition, communication, and oral intake. Safety measures are to avoid falls at home. The most common complications of the disease include: Neurocognitive decline (dementia) Blindness (e.g., optic atrophy) Malnutrition Aspiration pneumonia Death (5 to 6 years in the late infantile form)"}
{"id": "article-25045_32", "title": "Metachromatic Leukodystrophy -- Consultations", "content": "Regular consultations with followings specialists are generally needed: Pediatric and adult general neurologists Epileptologists Dietitians and nutritionists Gastroenterologists Genetic counselor and specialist Pediatrician Ophthalmologist", "contents": "Metachromatic Leukodystrophy -- Consultations. Regular consultations with followings specialists are generally needed: Pediatric and adult general neurologists Epileptologists Dietitians and nutritionists Gastroenterologists Genetic counselor and specialist Pediatrician Ophthalmologist"}
{"id": "article-25045_33", "title": "Metachromatic Leukodystrophy -- Deterrence and Patient Education", "content": "Patients often find it difficult to carry out activities of daily living as the condition worsens. Patients and family members should be properly counseled about the progressive nature of the disease and the prognosis. Some of the related complications and co-morbidities are gastroesophageal reflux, constipation, dental caries, impaired vision, among others. Pharmacological management, physical therapies, and family support can help prevent further decline of the patient and improve quality of life.", "contents": "Metachromatic Leukodystrophy -- Deterrence and Patient Education. Patients often find it difficult to carry out activities of daily living as the condition worsens. Patients and family members should be properly counseled about the progressive nature of the disease and the prognosis. Some of the related complications and co-morbidities are gastroesophageal reflux, constipation, dental caries, impaired vision, among others. Pharmacological management, physical therapies, and family support can help prevent further decline of the patient and improve quality of life."}
{"id": "article-25045_34", "title": "Metachromatic Leukodystrophy -- Deterrence and Patient Education", "content": "Metachromatic leukodystrophy is an autosomal recessive condition. Parents require counseling about the inheritance pattern of the condition if the family has a positive family history of the condition.", "contents": "Metachromatic Leukodystrophy -- Deterrence and Patient Education. Metachromatic leukodystrophy is an autosomal recessive condition. Parents require counseling about the inheritance pattern of the condition if the family has a positive family history of the condition."}
{"id": "article-25045_35", "title": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes", "content": "Metachromatic leukodystrophy is an autosomal recessive lysosomal disorder that results in a buildup of sulfatides that leads to the destruction of the myelin sheath, leading to progressive demyelination of the central and peripheral nervous system. Once the diagnosis is made, an interprofessional approach is vital.", "contents": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes. Metachromatic leukodystrophy is an autosomal recessive lysosomal disorder that results in a buildup of sulfatides that leads to the destruction of the myelin sheath, leading to progressive demyelination of the central and peripheral nervous system. Once the diagnosis is made, an interprofessional approach is vital."}
{"id": "article-25045_36", "title": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes", "content": "Medical centers with specialty teams can offer information about the disorder, coordinate care among specialists, help evaluate options, and provide treatment. Primary care physicians, neurology physicians, pathologists, radiologists, physiotherapists, among others, can form a collaborative team for the best possible outcome.\u00a0A physical therapist, occupational therapist, orthopedist, ophthalmologist, neuropsychologist, and other specialists may be involved are often needed for long term follow up and evaluation.\u00a0Working with a nutrition specialist (dietitian) can help provide proper nutrition. Eventually, it may become difficult to swallow food or liquid. This may require assistive feeding devices as the condition progresses.", "contents": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes. Medical centers with specialty teams can offer information about the disorder, coordinate care among specialists, help evaluate options, and provide treatment. Primary care physicians, neurology physicians, pathologists, radiologists, physiotherapists, among others, can form a collaborative team for the best possible outcome.\u00a0A physical therapist, occupational therapist, orthopedist, ophthalmologist, neuropsychologist, and other specialists may be involved are often needed for long term follow up and evaluation.\u00a0Working with a nutrition specialist (dietitian) can help provide proper nutrition. Eventually, it may become difficult to swallow food or liquid. This may require assistive feeding devices as the condition progresses."}
{"id": "article-25045_37", "title": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes", "content": "The role of the nurse in education is indispensable. The patient and the family need to know about the course of the disease, lifestyle modifications, and the need to follow up. The physical and occupational therapist should be consulted to assist with ambulation, use of an ambulatory device, and how to perform daily living activities. Couples with a family history of the disease should be offered genetic counseling during pregnancy.", "contents": "Metachromatic Leukodystrophy -- Enhancing Healthcare Team Outcomes. The role of the nurse in education is indispensable. The patient and the family need to know about the course of the disease, lifestyle modifications, and the need to follow up. The physical and occupational therapist should be consulted to assist with ambulation, use of an ambulatory device, and how to perform daily living activities. Couples with a family history of the disease should be offered genetic counseling during pregnancy."}
{"id": "article-25045_38", "title": "Metachromatic Leukodystrophy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Metachromatic Leukodystrophy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}